Literature DB >> 22904677

Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.

Paula Paulo1, Franclim R Ribeiro, Joana Santos, Diana Mesquita, Mafalda Almeida, João D Barros-Silva, Harri Itkonen, Rui Henrique, Carmen Jerónimo, Anita Sveen, Ian G Mills, Rolf I Skotheim, Ragnhild A Lothe, Manuel R Teixeira.   

Abstract

This work aimed to evaluate whether ETS transcription factors frequently involved in rearrangements in prostate carcinomas (PCa), namely ERG and ETV1, regulate specific or shared target genes. We performed differential expression analysis on nine normal prostate tissues and 50 PCa enriched for different ETS rearrangements using exon-level expression microarrays, followed by in vitro validation using cell line models. We found specific deregulation of 57 genes in ERG-positive PCa and 15 genes in ETV1-positive PCa, whereas deregulation of 27 genes was shared in both tumor subtypes. We further showed that the expression of seven tumor-associated ERG target genes (PLA1A, CACNA1D, ATP8A2, HLA-DMB, PDE3B, TDRD1, and TMBIM1) and two tumor-associated ETV1 target genes (FKBP10 and GLYATL2) was significantly affected by specific ETS silencing in VCaP and LNCaP cell line models, respectively, whereas the expression of three candidate ERG and ETV1 shared targets (GRPR, KCNH8, and TMEM45B) was significantly affected by silencing of either ETS. Interestingly, we demonstrate that the expression of TDRD1, the topmost overexpressed gene of our list of ERG-specific candidate targets, is inversely correlated with the methylation levels of a CpG island found at -66 bp of the transcription start site in PCa and that TDRD1 expression is regulated by direct binding of ERG to the CpG island in VCaP cells. We conclude that ETS transcription factors regulate specific and shared target genes and that TDRD1, FKBP10, and GRPR are promising therapeutic targets and can serve as diagnostic markers for molecular subtypes of PCa harboring specific fusion gene rearrangements.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904677      PMCID: PMC3421956          DOI: 10.1593/neo.12600

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  56 in total

1.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Authors:  Michele N Washington; Nancy L Weigel
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

2.  Associations between PIWI proteins and TDRD1/MTR-1 are critical for integrated subcellular localization in murine male germ cells.

Authors:  Kanako Kojima; Satomi Kuramochi-Miyagawa; Shinichiro Chuma; Takashi Tanaka; Norio Nakatsuji; Tohru Kimura; Toru Nakano
Journal:  Genes Cells       Date:  2009-09-07       Impact factor: 1.891

3.  Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.

Authors:  Rogier P J Schroeder; Monique de Visser; Wytske M van Weerden; Corrina M A de Ridder; Suzanne Reneman; Marleen Melis; Wout A P Breeman; Eric P Krenning; Marion de Jong
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

4.  Gastrin-releasing peptide receptor in breast cancer mediates cellular migration and interleukin-8 expression.

Authors:  Celia Chao; Kirk Ives; Helen L Hellmich; Courtney M Townsend; Mark R Hellmich
Journal:  J Surg Res       Date:  2009-05-03       Impact factor: 2.192

5.  Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.

Authors:  Mari Björkman; Kristiina Iljin; Pasi Halonen; Henri Sara; Elisa Kaivanto; Matthias Nees; Olli P Kallioniemi
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

Review 6.  ETS gene fusions in prostate cancer.

Authors:  Jeremy P Clark; Colin S Cooper
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

7.  Mili interacts with tudor domain-containing protein 1 in regulating spermatogenesis.

Authors:  Jianquan Wang; Jonathan P Saxe; Takashi Tanaka; Shinichiro Chuma; Haifan Lin
Journal:  Curr Biol       Date:  2009-04-02       Impact factor: 10.834

8.  Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

Authors:  Jianghua Wang; Yi Cai; Wendong Yu; Chengxi Ren; David M Spencer; Michael Ittmann
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

9.  High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications.

Authors:  Achim Fleischmann; Beatrice Waser; Jean Claude Reubi
Journal:  Endocr Relat Cancer       Date:  2009-06       Impact factor: 5.678

10.  Loss of the Mili-interacting Tudor domain-containing protein-1 activates transposons and alters the Mili-associated small RNA profile.

Authors:  Michael Reuter; Shinichiro Chuma; Takashi Tanaka; Thomas Franz; Alexander Stark; Ramesh S Pillai
Journal:  Nat Struct Mol Biol       Date:  2009-05-24       Impact factor: 15.369

View more
  31 in total

1.  Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.

Authors:  João D Barros-Silva; Paula Paulo; Anne Cathrine Bakken; Nuno Cerveira; Marthe Løvf; Rui Henrique; Carmen Jerónimo; Ragnhild A Lothe; Rolf Inge Skotheim; Manuel R Teixeira
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 3.  Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.

Authors:  Ian G Mills
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

4.  Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.

Authors:  Milan S Geybels; Karen D McCloskey; Ian G Mills; Janet L Stanford
Journal:  Prostate       Date:  2016-10-18       Impact factor: 4.104

5.  Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.

Authors:  Kirill Litovkin; Steven Joniau; Evelyne Lerut; Annouschka Laenen; Olivier Gevaert; Martin Spahn; Burkhard Kneitz; Sofie Isebaert; Karin Haustermans; Monique Beullens; Aleyde Van Eynde; Mathieu Bollen
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-18       Impact factor: 4.553

Review 6.  ETS transcription factors in embryonic vascular development.

Authors:  Michael P Craig; Saulius Sumanas
Journal:  Angiogenesis       Date:  2016-04-28       Impact factor: 9.596

7.  Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Authors:  Martine P Roudier; Brian R Winters; Ilsa Coleman; Hung-Ming Lam; Xiaotun Zhang; Roger Coleman; Lisly Chéry; Lawrence D True; Celestia S Higano; Bruce Montgomery; Paul H Lange; Linda A Snyder; Shiv Srivastava; Eva Corey; Robert L Vessella; Peter S Nelson; Aykut Üren; Colm Morrissey
Journal:  Prostate       Date:  2016-03-16       Impact factor: 4.104

8.  A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype.

Authors:  Guangjing Zhu; Zhi Liu; Jonathan I Epstein; Christine Davis; Christhunesa S Christudass; H Ballentine Carter; Patricia Landis; Hui Zhang; Joon-Yong Chung; Stephen M Hewitt; M Craig Miller; Robert W Veltri
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-09-24       Impact factor: 4.254

9.  TMEM45B, up-regulated in human lung cancer, enhances tumorigenicity of lung cancer cells.

Authors:  Rui Hu; Fengqing Hu; Xiao Xie; Lei Wang; Guoqing Li; Tong Qiao; Mingsong Wang; Haibo Xiao
Journal:  Tumour Biol       Date:  2016-05-26

10.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.